Aryl hydrocarbon receptor signaling
|
1E-03
|
5.59E-02
|
HSPB3, CDKN2A, MYC, FOS, GSTM2, ALDH1A1, NQO1, TGFB2, HSPB1
|
HGF Signaling
|
3E-03
|
6.67E-02
|
CDKN2A, MET, FOS, MAP3K6, MAP3K13, ETS2, ELK3
|
LPS/IL-1 mediated inhibition of RXR function
|
7E-03
|
4.18E-02
|
CHST2, ABCB1, GSTM2, ALDH1A1, SLC27A2, HS3ST1, CPT1C, PLTP, HMGCS1, IL1RAP
|
Hepatic fibrosis/hepatic stellate cell activation
|
1.6E-02
|
4.79E-02
|
MET, TIMP1, ACTA2, TGFB2, IGFBP5, IL1RAP, COL3A1
|
Retinoate biosynthesis I
|
1.8E-02
|
7.89E-02
|
ALDH1A1, RBP7, AKR1C3
|
Methylglyoxal degradation III
|
1.68E-02
|
8.7E-02
|
AKR1C3, AKR1B1
|
S-methyl-5′-thioadenosine degradation II
|
1.9E-02
|
1.67E-01
|
MTAP
|
Histamine biosynthesis
|
1.9E-02
|
3.33E-01
|
HDC
|
Retinol biosynthesis
|
2.5E-02
|
4.92E-02
|
DHRS3, RBP7, LPL
|
Cell Cycle: G1/S checkpoint regulation
|
2.7E-02
|
6.06E-02
|
CDKN2A, MYC, HDAC9, TGFB2
|
The visual cycle
|
2.9E-02
|
7.14E-02
|
DHRS3, RBP7
|
PXR/RXR activation
|
3.2E-02
|
4.6E-02
|
ABCB1, GSTM2, ALDH1A1, FOXO1
|
Glutamine biosynthesis I
|
3.8E-02
|
1.25E-01
|
GLUL
|
Thyroid cancer signaling
|
4.2E-02
|
7.14E-02
|
PPARG, MYC, NTF3
|
Mitochondrial L-carnitine shuttle pathway |
4.2E-02 |
9.09E-02 |
SLC27A2, CPT1C |